RESUMO
BACKGROUND: This study compares an endoscopic microcatheter and a nebulizer for delivering Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). METHODS: This is an in vitro and ex vivo study in an established model (inverted bovine urinary bladder). Four parameters were compared to determine the performance of a micro-perforated endoscopic spray catheter vs. state-of-the art, nozzle technology: (1) surface coverage and pattern with methylene blue on blotting paper at three different distances; (2) median aerodynamic diameter (MAD) of aerosol droplets with three different solutions (H2O, Glc 5% and silicon oil); (3) depth of tissue penetration of doxorubicin (DOX) and (4) tissue concentration of cisplatin (CIS) and DOX using standard clinical solutions. RESULTS: The spray area covered by the microcatheter was larger (p < 0.001) but its pattern was inhomogenous than with the nozzle technology. We found that aerosol droplets were larger in the test group than in the control group for all three solutions tested. Median tissue penetration of DOX was lower (980 µm) with the microcatheter than with the nebulizer (1235 µm) and distribution was more heterogeneous ( = 0.003) with the microcatheter. The median tissue concentration of DOX and CIS was lower and concentration of DOX was more heterogeneous with the microcatheter (p = 0.002). CONCLUSIONS: This investigation has revealed that microcatheter technology generates larger aerosol droplet size, less drug tissue penetration and lower drug tissue concentration than the current nozzle technology. In the absence of clinical studies, use of microcatheters for delivering PIPAC can not be recommended at this stage.
Assuntos
Aerossóis/uso terapêutico , Tratamento Farmacológico/métodos , Nebulizadores e Vaporizadores/normas , Aerossóis/farmacologia , Animais , BovinosRESUMO
Recent development regarding mixture of H2 (concentration of ~66%) with O2 (concentration of ~34%) for medical purpose, such as treatment of coronavirus disease-19 (COVID-19) patients, is introduced. Furthermore, the design principles of a hydrogen inhaler which generates mixture of hydrogen (~66%) with oxygen (~34%) for medical purpose are proposed. With the installation of the liquid blocking module and flame arresters, the air pathway of the hydrogen inhaler is divided by multiple isolation zones to prevent any unexpected explosion propagating from one zone to the other. An integrated filtering/cycling module is utilized to purify the impurity, and cool down the temperature of the electrolytic module to reduce the risk of the explosion. Moreover, a nebulizer is provided to selectively atomize the water into vapor which is then mixed with the filtered hydrogen-oxygen mix gas, such that the static electricity of a substance hardly occurs to reduce the risk of the explosion. Furthermore, hydrogen concentration detector is installed to reduce the risk of hydrogen leakage. Result shows that the hydrogen inhaler implementing the aforesaid design rules could effectively inhibit the explosion, even ignition at the outset of the hydrogen inhaler which outputs hydrogen-oxygen gas (approximately 66% hydrogen: 34% oxygen).
Assuntos
COVID-19/terapia , Hidrogênio/administração & dosagem , Nebulizadores e Vaporizadores , Oxigenoterapia/métodos , Oxigênio/administração & dosagem , Explosões/prevenção & controle , Humanos , Nebulizadores e Vaporizadores/normas , Oxigenoterapia/normas , Eletricidade Estática/efeitos adversos , VolatilizaçãoRESUMO
BACKGROUND: Nebulization of antimicrobial drugs such as tobramycin and colistin is a cornerstone in the treatment of patients with cystic fibrosis (CF) infected with Pseudomonas aeruginosa. However, nebulization has a high treatment burden. The Twincer™ is a dry powder inhaler specifically developed for the inhalation of antibiotics such as colistin. The aim of this study was to compare patient outcomes and experience with colistin dry powder by the Twincer with nebulization of colistin or tobramycin in adult CF patients in a real-life setting. METHODS: This was a retrospective study from 01-01-2015 until 01-07-2018. Effectiveness was evaluated by comparing FEV1 decline and exacerbation rate during a mean of 4.1 years of nebulization therapy prior to the initiation of the Twincer against the same values during a mean of 1.7 years of treatment with the Twincer. RESULTS: Twenty-one patients were evaluated, of whom twelve could be included in the effectiveness analysis, with a total of twenty patient years. Of all patients 71.4% preferred therapy with the Twincer over nebulization. Twincer use resulted in high treatment adherence with an average adherence rate of 92.5%. There was no significant difference in annual decline in FEV1%pred prior to and after start changing from nebulization to the use of the Twincer powder inhaler (median decline -1.56 [-5.57-5.31] and 1.35 [-8.45-6.36]) respectively, p = 0.45 (linear mixed effect model)). No significant difference was found in the number of intravenous or combined total intravenous and oral antibiotic courses during Twincer therapy compared to when using nebulization (1.68 and 2.49 courses during Twincer therapy versus 1.51 and 2.94 courses during nebulization, p = 0.88 and p = 0.63). CONCLUSION: Colistin dry powder inhalation with the Twincer is a more patient friendly alternative to nebulization, and we did not observe significant differences in the clinical outcome, regarding lung function and exacerbation rates.
Assuntos
Antibacterianos/administração & dosagem , Colistina/administração & dosagem , Fibrose Cística/microbiologia , Nebulizadores e Vaporizadores/normas , Infecções por Pseudomonas/tratamento farmacológico , Administração por Inalação , Adolescente , Adulto , Antibacterianos/uso terapêutico , Colistina/uso terapêutico , Fibrose Cística/complicações , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infecções por Pseudomonas/complicaçõesRESUMO
BACKGROUND: Conflicting evidence of nebulized lidocaine use in bronchoscopy still exist. This study will identify whether there is any difference in various patient-related, physician-related, or procedure-related outcomes with and without lidocaine nebulization before the procedure. METHOD: The authors performed a search in 4 electronic databases, including Pubmed, Scopus, Virtual Health Library, and Google Scholar from inception to August 2019. Data on patient-reported and physician-reported outcomes, doses of sedation, and lidocaine were extracted and pooled into standardized mean difference (SMD) and mean difference (MD) using the random-effect model. RESULTS: Seven randomized controlled trials with 1366 patients were included. Cough was not different between the nebulized lidocaine group and no nebulized lidocaine group (SMD, -0.12; 95% confidence interval, -0.82 to 0.59; I, 95%; P=0.75), so as operator's satisfaction score, ease of the procedure, patient's discomfort, and unwillingness to repeat the procedure. Additional nebulized lidocaine group required higher lidocaine dose (MD, 81.93; 95% confidence interval, 17.14-146.71). Studies using only local anesthesia favored the "no additional lidocaine" group in improving cough, operator's satisfaction score, and ease of the procedure. Subgroup analysis of studies using moderate sedation showed a decrease in midazolam dose and duration of the procedure in the "additional nebulized lidocaine group." CONCLUSION: Additional administration of nebulized lidocaine increased the total dose of lidocaine used and did not improve cough symptoms, operator-satisfaction score, ease of the procedure, and willingness to repeat the procedure. Subgroup analysis of studies using moderate sedation showed a decrease in midazolam use and in procedure duration but the clinical significance of these findings is uncertain.
Assuntos
Anestésicos Locais/administração & dosagem , Broncoscopia/efeitos adversos , Tosse/prevenção & controle , Lidocaína/administração & dosagem , Adjuvantes Anestésicos/administração & dosagem , Adulto , Idoso , Broncoscopia/métodos , Broncoscopia/estatística & dados numéricos , Estudos de Casos e Controles , Sedação Consciente/métodos , Sedação Consciente/estatística & dados numéricos , Tosse/diagnóstico , Feminino , Humanos , Masculino , Midazolam/administração & dosagem , Pessoa de Meia-Idade , Nebulizadores e Vaporizadores/normas , Medidas de Resultados Relatados pelo Paciente , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
The design of electronic cigarette (EC) atomizing units has evolved since their introduction over 10 years ago. The purpose of this study was to evaluate atomizer design in ECs sold between 2011-2017. Atomizers from 34 brands representing three generations of ECs were dissected and photographed using a stereoscopic microscope. Five distinct atomizer design categories were identified in first generation products (cig-a-like/cartomizer) and three categories were found in the third generation. Atomizers in most cig-a-like ECs contained a filament, thick wire, wire joints, air-tube, wick, sheath, and fibers, while some later models lacked some of these components. Over time design changes included an increase in atomizer size; removal of solder joints between wires; removal of Polyfil fibers; and removal of the microprocessor from Vuse. In second and third generation ECs, the reservoirs and batteries were larger, and the atomizing units generally lacked a thick wire, fibers, and sheath. These data contribute to an understanding of atomizer design and show that there is no single design for ECs, which are continually evolving. The design of the atomizer is particularly important as it affects the performance of ECs and what transfers into the aerosol.
Assuntos
Aerossóis/normas , Sistemas Eletrônicos de Liberação de Nicotina/normas , Desenho de Equipamento/normas , Desenho de Equipamento/tendências , Nebulizadores e Vaporizadores/normas , Nebulizadores e Vaporizadores/tendências , PrevisõesRESUMO
BACKGROUND: The daily burden of health maintenance for children and families with cystic fibrosis (CF) is immense with respect to time and complexity of care. Infection control practices, specifically nebulizer cleaning and disinfection, are a recommended component of home health care for CF families due to colonization of home respiratory equipment with lung pathogens. To better inform education interventions at our center, we were interested in studying how families' views on infection prevention and awareness of CF Foundation infection prevention and control (IP&C) guidelines correlate with actual home nebulizer care and the presence of microorganisms on their nebulizers. METHODS: Twenty families who have children with CF were surveyed to better understand attitudes toward infection prevention, awareness of CFF IP&C guidelines and nebulizer cleaning and disinfection practices in the home. Their nebulizers were also cultured for microbes to correlate recovery with infection control behaviors. RESULTS: A subset of families recognizes the importance of germ avoidance but do not recognize nebulizer cleaning and disinfection as very important for infection control practices. Decreased frequency of disinfection, but not cleaning, was correlated with the recovery of organisms on the nebulizers. CONCLUSIONS: The study questionnaire results identify a gap between recognizing the importance of infection prevention and consistently implementing CFF IP&C guidelines in the home. This demonstrates the need at our center for new educational interventions to promote cleaning and disinfection of home nebulizers after each use as recommended by the CFF.
Assuntos
Infecções Bacterianas/prevenção & controle , Efeitos Psicossociais da Doença , Fibrose Cística , Desinfecção , Contaminação de Equipamentos/prevenção & controle , Controle de Infecções , Nebulizadores e Vaporizadores , Autocuidado , Administração por Inalação , Atitude , Criança , Fibrose Cística/tratamento farmacológico , Fibrose Cística/psicologia , Desinfecção/métodos , Desinfecção/normas , Saúde da Família , Feminino , Humanos , Controle de Infecções/métodos , Controle de Infecções/normas , Masculino , Nebulizadores e Vaporizadores/microbiologia , Nebulizadores e Vaporizadores/normas , Avaliação das Necessidades , Autocuidado/métodos , Autocuidado/psicologiaRESUMO
Fifty-two meshes of e-flow rapid® were characterized for tobramycin delivery with a laser diffractometer after 6â¯months of home use by cystic fibrosis patients treated with various nebulized drugs. Three meshes were out of order and 30 considered to be defective for tobramycin delivery. The use of the specific mesh cleaning shower system permitted 14 defective meshes to be in the expected range of nebulized volume.
Assuntos
Fibrose Cística/tratamento farmacológico , Falha de Equipamento , Nebulizadores e Vaporizadores , Infecções por Pseudomonas/prevenção & controle , Tobramicina/uso terapêutico , Administração por Inalação , Antibacterianos/uso terapêutico , Contaminação de Equipamentos/prevenção & controle , Análise de Falha de Equipamento , Humanos , Nebulizadores e Vaporizadores/microbiologia , Nebulizadores e Vaporizadores/normas , Autocuidado/instrumentação , Autocuidado/métodosRESUMO
BACKGROUND: Endobronchial administration of lidocaine is commonly used for cough suppression during diagnostic bronchoscopy. Recently, nebulization of lidocaine during bronchoscopies under deep sedation with fiberoptic intubation using a distinct spray catheter has been shown to have several advantages over conventional lidocaine administration via syringe. However, there are no data about this approach in bronchoscopies performed under moderate sedation. Therefore, this study compared the tolerability and safety of nebulized lidocaine with conventional lidocaine administration via syringe in patients undergoing bronchoscopy with moderate sedation. METHODS: Patients requiring diagnostic bronchoscopy were randomly assigned to receive topical lidocaine either via syringe or via nebulizer. Endpoints were consumption of lidocaine and sedative drugs, as well as patient tolerance and safety. RESULTS: Sixty patients were included in the study (n = 30 in each group). Patients required lower doses of endobronchial lidocaine when given via nebulizer versus syringe (164.7 ± 20.8 mg vs. 250.4 ± 42.38 mg; p < 0.0001) whereas no differences in the dosage of sedative drugs were observed between the two groups (all p > 0.05). Patients in the nebulizer group had higher mean oxygen saturation (96.19 ± 2.45% vs. 94.21 ± 3.02%; p = 0.0072) and a lower complication rate (0.3 ± 0.79 vs. 1.17 ± 1.62 per procedure; p = 0.0121) compared with those in the syringe group. CONCLUSIONS: Endobronchial lidocaine administration via nebulizer was well-tolerated during bronchoscopies under moderate sedation and was associated with reduced lidocaine consumption, a lower complication rate and better oxygenation compared with lidocaine administration via syringe. TRIAL REGISTRATION: The study was registered with clinicaltrials.gov ( NCT02262442 ; 13th October 2014).
Assuntos
Anestésicos Locais/administração & dosagem , Broncoscopia/normas , Sedação Consciente/normas , Lidocaína/administração & dosagem , Nebulizadores e Vaporizadores/normas , Maleabilidade , Administração Tópica , Idoso , Broncoscopia/instrumentação , Sedação Consciente/instrumentação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Consumo de Oxigênio/efeitos dos fármacos , Consumo de Oxigênio/fisiologiaRESUMO
OBJECTIVES: For electronic nicotine delivery systems (ENDS), also commonly called e-cigarettes, coil temperature is a factor in the potential production of toxic chemical constituents. However, data are lacking regarding the temperatures that are achieved in the latest generation of these devices. Fourth-generation ENDS are capable of producing heating coil temperatures well above e-liquid boiling points, and allow the user to monitor and set the heating coil temperature during a puff. In this study, we evaluate the accuracy and consistency of the temperature measurement and control settings for different brands of fourth-generation ENDS. METHODS: A study was performed using three commercially available, fourth-generation ENDS. The atomizer coil temperatures were obtained from the device (using the EScribe software) reading and from thermocouples attached to the coils during simulated puffing conditions. In addition, aerosol temperatures were measured inside the atomizer and at the mouthpiece. RESULTS: Measured temperatures varied widely across samples taken from the same brand. For example, thermocouple measurements for one unit were 40 Celsius (°C) below the 300 °C set point, while another unit of the same brand exceeded the set point by more than 100 °C. We observed a significant variation in temperature (approximately 100 °C) along the length of the coil in some cases. CONCLUSIONS: The possibility of wide temperature variation across ENDS samples, as well as variations between maximum coil temperatures and internal temperature readings, may have implications for studies that seek to determine correlations between coil temperature and toxin generation.
Assuntos
Sistemas Eletrônicos de Liberação de Nicotina/normas , Nebulizadores e Vaporizadores/normas , Nicotina/química , Aerossóis/normas , Humanos , Temperatura , TermômetrosRESUMO
ABSTRACT CONTEXT AND OBJECTIVE: Treatment of asthma implies inhalation of specific drugs to reach high concentrations in the respiratory tree and ensure low drug bioavailability and few adverse effects. This study aimed to evaluate the effectiveness of the inhalation technique among outpatients with asthma. DESIGN AND SETTING: Tertiary-care hospital-based cross-sectional study in Rio de Janeiro. METHODS: We evaluated inhalation practices in a convenience sample. A questionnaire was used to investigate sociodemographic data and assess disease control level, duration of use of the inhalation device, length of treatment and previous instructions provided by the prescribing physician. Patients demonstrated their inhalation technique using empty devices, and their technique was considered correct when all steps were appropriately performed or when errors did not interfere with the treatment outcome. RESULTS: Among the 71 participants, 53 (74.7%) had been using the same inhaler device for at least two years and 41 (57.8%) had been under treatment for two years or more. Twelve (17.1%) said that they had been taught once and 57 (81.4%) at least twice, while one (1.4%) reported not having received any guidance regarding use of inhaler devices. Eighteen patients (25.3%) presented controlled asthma and 28 (39.5%) performed the inhalation technique correctly. Incorrect technique was associated with fewer evaluations of the inhalation technique (P =0.04) and uncontrolled asthma (P = 0.01). CONCLUSIONS: Less than half of the sample performed the inhalation technique correctly. Incorrect inhalation technique was related to lower number of evaluations of the use of the inhalation device and uncontrolled asthma.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Adulto Jovem , Asma/tratamento farmacológico , Nebulizadores e Vaporizadores/normas , Fatores Socioeconômicos , Nebulizadores e Vaporizadores/estatística & dados numéricos , Brasil , Estudos Transversais , Inquéritos e QuestionáriosRESUMO
Many patients make critical user technique errors when using pressurised metered dose inhalers (pMDIs) which reduce the clinical efficacy of respiratory medication. Such critical errors include poor actuation coordination (poor timing of medication release during inhalation) and inhaling too fast (peak inspiratory flow rate over 90 L/min). Here, we present a novel audio-based method that objectively assesses patient pMDI user technique. The Inhaler Compliance Assessment device was employed to record inhaler audio signals from 62 respiratory patients as they used a pMDI with an In-Check Flo-Tone device attached to the inhaler mouthpiece. Using a quadratic discriminant analysis approach, the audio-based method generated a total frame-by-frame accuracy of 88.2% in classifying sound events (actuation, inhalation and exhalation). The audio-based method estimated the peak inspiratory flow rate and volume of inhalations with an accuracy of 88.2% and 83.94% respectively. It was detected that 89% of patients made at least one critical user technique error even after tuition from an expert clinical reviewer. This method provides a more clinically accurate assessment of patient inhaler user technique than standard checklist methods.
Assuntos
Asma/tratamento farmacológico , Broncodilatadores/administração & dosagem , Monitorização Fisiológica/instrumentação , Nebulizadores e Vaporizadores/normas , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Som , Administração por Inalação , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Monitorização Fisiológica/métodos , Adulto JovemRESUMO
ABSTRACT To assess the impact that educational interventions to improve inhaler techniques have on the clinical and functional control of asthma and COPD, we evaluated 44 participants before and after such an intervention. There was a significant decrease in the number of errors, and 20 patients (46%) significantly improved their technique regarding prior exhalation and breath hold. In the asthma group, there were significant improvements in the mean FEV1, FVC, and PEF (of 6.4%, 8.6%, and 8.3% respectively). Those improvements were accompanied by improvements in Control of Allergic Rhinitis and Asthma Test scores but not in Asthma Control Test scores. In the COPD group, there were no significant variations. In asthma patients, educational interventions appear to improve inhaler technique, clinical control, and functional control.
RESUMO Para avaliar o impacto do ensino da técnica inalatória no controle clínico e funcional de pacientes com asma ou DPOC, incluíram-se 44 participantes antes e após essa intervenção. Houve uma diminuição significativa no número de erros cometidos, sendo que 20 pacientes (46%) melhoraram significativamente sua técnica na expiração prévia e apneia final. No grupo asma, houve significativa melhora nas médias de FEV1 (6,4%), CVF (8,6%) e PFE (8,3%), e essa melhora correlacionou-se com os resultados no Control of Allergic Rhinitis and Asthma Test, mas não com os do Asthma Control Test. No grupo DPOC, não houve variações significativas. O ensino da técnica inalatória parece melhorar seu desempenho e os controles clínico e funcional em pacientes com asma.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Asma/prevenção & controle , Nebulizadores e Vaporizadores/normas , Educação de Pacientes como Assunto/métodos , Doença Pulmonar Obstrutiva Crônica/prevenção & controle , Portugal , Educação de Pacientes como Assunto/normas , Estudos Controlados Antes e DepoisRESUMO
INTRODUCTION: Improving health-related quality of life (HRQoL) in COPD patients is an important pharmacotherapeutic objective. This study investigated the extent, consistency, and durability of tiotropium maintenance therapy impact on HRQoL in moderate-to-very severe COPD. METHODS: Patients received once-daily tiotropium 18 µg (n = 5244) or placebo (n = 4799) via HandiHaler® (10 trials), or once-daily tiotropium 5 µg (n = 2622) or placebo (n = 2618) via Respimat® inhaler (3 trials). St George's Respiratory Questionnaire (SGRQ) total scores were measured at baseline, and 6 months (13 trials) and 1 year (9 trials) from treatment start. Adjusted mean differences between treatments for change from baseline in total scores were calculated at each time-point for each trial. Responder and deteriorator rates (decrease or increase in score ≥4 units from baseline, respectively), net benefit (responder rate increase plus deteriorator rate decrease), and cumulative improvement and deterioration were determined. RESULTS: Adjusted mean total score differences between treatments for change from baseline were significant (p < 0.05) in favor of tiotropium in 10/13 trials at 6 months and in 8/9 trials at 1 year. In all trials, estimated differences in responder rates between treatments favored tiotropium (significant [p < 0.05]: 5/13 trials at 6 months; 8/9 trials at 1 year). Net benefit favored tiotropium and cumulative improvement rates were consistently greater and deterioration rates consistently lower for tiotropium versus placebo. CONCLUSIONS: Tiotropium maintenance therapy significantly and consistently improved HRQoL in moderate-to-very severe COPD patients in a durable manner. These results may provide a benchmark for assessing benefits on HRQoL of other COPD treatments.
Assuntos
Antagonistas Muscarínicos/administração & dosagem , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Qualidade de Vida/psicologia , Brometo de Tiotrópio/administração & dosagem , Administração por Inalação , Adulto , Idoso , Idoso de 80 Anos ou mais , Broncodilatadores/uso terapêutico , Feminino , Volume Expiratório Forçado/efeitos dos fármacos , Nível de Saúde , Humanos , Masculino , Metanálise como Assunto , Pessoa de Meia-Idade , Antagonistas Muscarínicos/farmacologia , Nebulizadores e Vaporizadores/normas , Doença Pulmonar Obstrutiva Crônica/psicologia , Testes de Função Respiratória/métodos , Índice de Gravidade de Doença , Fumar/epidemiologia , Brometo de Tiotrópio/farmacologia , Resultado do Tratamento , Capacidade Vital/efeitos dos fármacosRESUMO
Aerosol delivery equipment used to administer inhaled medications includes the nebulizer, positive expiratory pressure devices added to the nebulizer, and valved holding chambers (spacers). These devices are semi-critical medical devices, and as such, infection prevention and control (IPC) guidelines recommend that they be cleaned, disinfected, rinsed with sterile water, and air-dried. There is confusion surrounding the care of aerosol devices because of inconsistencies in the various published IPC guidelines, lack of a standard of practice among institutions and respiratory therapists (RTs), and manufacturer's instructions for use of these devices are not always compatible with guidelines or practice. Challenges lie in awareness of IPC guidelines and establishing a standard for the care of aerosol delivery devices among all stakeholders/manufacturers, governments, vendors, and users. The latest IPC guideline from the Cystic Fibrosis Foundation, reviewed and endorsed by the Society for Healthcare Epidemiology of America and the Association for Professionals in Infection Control, has a recommendation for disposable nebulizers and a recommendation for reusable nebulizers. Reusable nebulizers should be cleaned, disinfected, rinsed with sterile water (if using a cold disinfectant), and air-dried between uses. The mouthpiece/mask of disposable nebulizers should be wiped with an alcohol pad, the residual volume should be rinsed out with sterile water after use, and the nebulizer should be replaced every 24 h. The RT plays a significant and responsible role in providing and teaching aerosol therapy to patients. The RT and all stakeholders need to work together to provide a standard of care for the safe use of aerosol delivery devices.
Assuntos
Desinfecção/normas , Controle de Infecções/normas , Nebulizadores e Vaporizadores/normas , Terapia Respiratória/instrumentação , Administração por Inalação , Aerossóis/administração & dosagem , Contaminação de Equipamentos/prevenção & controle , HumanosRESUMO
OBJECTIVE: To design a combined dynamic inhalation device for testing the toxicity induced by moxa smoking. METHODS: The new apparatus (Patent No. 201120101911.5) includes air renewal and recycling systems, a gas generating device, a gas control unit, and a device to measure and control temperature and humidity. Sprague-Dawley rats were tested for acute and sub-chronic toxicity after exposure to moxa-burning smoke. RESULTS: We found an LC50 of 1.2 x 10(4) mg/m3 in the acute toxicity assays. In sub-chronic toxicity tests the organ coefficients studied showed no significant differences within rats groups of the same gender after treatment with moxa smoke or a month of recovery. However, mean gray degree of lung 70 heat shock protein (HSP70) was significantly elevated in the high dose group in comparison with the low dose group (P < 0.05); mean gray degree, mean optical density, gross area of HSP70 in other organs and caspase-9 parameters showed no significant differences between groups. CONCLUSION: These results suggest that moxa smoke had no overt toxicity in rats. This work provides evidence and reference for the design of dynamic inhalation exposure systems.
Assuntos
Moxibustão/instrumentação , Nebulizadores e Vaporizadores/normas , Fumaça/análise , Animais , Desenho de Equipamento , Feminino , Proteínas de Choque Térmico HSP72/metabolismo , Pulmão/metabolismo , Pulmão/patologia , Masculino , Ratos , Ratos Sprague-Dawley , Fumaça/efeitos adversosRESUMO
BACKGROUND: Nebulised medicines contribute to the high treatment burden experienced by patients with cystic fibrosis (CF). OBJECTIVES: This study explored experiences of adult patients with CF when using nebulised medicines, factors impacting on their adherence to nebulised therapy and strategies they used to facilitate adherence. SETTING: Community setting, in Sydney, Australia. METHODS: Ten patients with CF were recruited through a CF patient organisation. Semi-structured face-to-face interviews were conducted, addressing the study objectives. Interviews were audio-recorded, transcribed verbatim and content analysed for anticipated and emergent themes. MAIN OUTCOME MEASURE: Experiences with using nebulised medicines; and barriers and facilitators of adherence to nebulised medicines. RESULTS: Participants' age ranged from 22 to 45 years, with half being male. Four broad themes (with more specific sub-themes) were identified from the interviews: experiences with using nebulised medicines (cleaning nebuliser, time taken to use nebuliser medicine, flexibility in use of nebuliser); feelings about using nebulised medicines (necessary/important, dislike, part of life); factors impacting non-adherence (time consuming therapy, side effects/effects of medicine, work/social demands, lack of perceived importance); factors and strategies facilitating adherence (perceived medicine importance, habit/routine, support, health benefits, technology/medicine dose form, timetabling). CONCLUSIONS: Nebulised therapy for cystic fibrosis patients takes a substantial amount of time, with patients trying to alter their routine to incorporate nebulising into their daily lives. However there are still many factors that lead to low adherence, including work/social demands and travelling. Patients balance the necessity for nebulised therapy against the barriers, and engage in intentional non-adherence at times. Future strategies and resources should target and address specific factors identified by patients with CF as being important and impacting their adherence to nebulised medicines.
Assuntos
Fibrose Cística/tratamento farmacológico , Fibrose Cística/psicologia , Conhecimentos, Atitudes e Prática em Saúde , Adesão à Medicação/psicologia , Nebulizadores e Vaporizadores/normas , Pesquisa Qualitativa , Administração por Inalação , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto JovemRESUMO
As doenças do trato respiratório têm uma elevada prevalência emnosso meio. A via inalatória é a preferida para a administração da terapia. Vários dispositivos, com diferentes características, estão disponíveis no mercado. Esta revisão teve o objetivo de descrever os tipos de dispositivos, suas vantagens e desvantagens, e indicações de uso conforme cada faixa etária, além de abordar alguns aspectos técnicos relevantes para a obtenção de melhores resultados com a terapia inalatória. Evidências científicas enfatizam novas formas de administração de medicação inalatória. Nebulizadores convencionais apresentam numerosos inconvenientes. Aerossóis com espaçadores/aerocâmaras permitem melhora na deposição pulmonar, resultando, principalmente em pacientes sem coordenação adequada, em uma melhor relação custo-benefício do que outros métodos tradicionalmente utilizados. Naqueles que conseguem gerar altos fluxos inspiratórios, os inaladores de pó seco podem ser utilizados.
The prevalence of respiratory diseases is high in Brazil. Inhalation isthe preferred route of delivery for therapy. Various inhalation devices, with different characteristics, are available. The objective of this review was to describe those devices, their advantages, disadvantages, and indications for each age group, as well as to address certain relevant technical aspects of obtaining optimal results with inhalation therapy. New means of delivering inhaled therapy have been described. Conventional nebulizers have a number of disadvantages. Aerosol inhalation via spacers or holding chambers seems to be another method, resulting, specifically in patients without adequate coordination, in a relative superior cost-benefit relationship in comparison with traditional methods. In patients who can generate high inspiratory flow rates, dry power inhalers can be used.
Assuntos
Humanos , Masculino , Feminino , Administração por Inalação , Aerossóis/administração & dosagem , Doenças Respiratórias/epidemiologia , Nebulizadores e Vaporizadores/normas , Nebulizadores e Vaporizadores , Terapia RespiratóriaRESUMO
We present this document as a guide to preparing a specific institutional pre-anaesthesia checklist, as recommended in the Helsinki declaration on patient safety in anaesthesiology. Also, the recently recommended WHO "safe surgery check-list" includes a check-list for anaesthesia. A working group was established in accordance with the charter of the Spanish Society of Anaesthesiology and Resuscitation (Sociedad Española de Anestesiología y Reanimación [SEDAR]). The new patient safety culture introduced into medicine, and the recommendations of European anaesthesia societies has led us to design and update protocols in order to improve results in this important part of our speciality. We have prepared these recommendations or guidelines using, as examples, updates of pre-anaesthesia check-lists by other American (ASA), British, or Canadian societies of anaesthesia. With that aim, we enlisted the help of anaesthesia ventilator experts and the participation and advice of experienced anaesthesiologists from all parts of Spain. After various corrections and modifications, the document was available at www.sedar.es, so that any anaesthesiologist could propose any correction, or give their opinion. Finally, these guidelines have been approved by the SEDAR Board of Directors, before it was sent for publication in this journal. The aims of this document are to provide: a guideline applicable to all anaesthesia machines, a descriptive pre-anaesthesia check-list that include everything necessary for the anaesthesia procedure, and a resumed check-list to be available in all the anaesthesia machines or other equivalent, but prepared for each institution, which should include anaesthetic equipment and drugs. So, in order to ensure the aims and requirements of the European Board of Anaesthesiology, the European Society of Anaesthesiology, and the WHO are met, each institution should have a protocol for checking equipment and drugs. These guidelines are applicable to any anaesthesia equipment, enabling every institution to develop their own checking protocols, adapted to their anaesthesia machines and their procedures. With the consent of the SEDAR, this group will collaborate with anaesthesia machines providers in order to develop specific checklists for each of their models that will be available at www.sedar.es.
Assuntos
Anestesiologia/normas , Cuidados Pré-Operatórios/normas , Anestesia por Inalação/instrumentação , Anestesia por Inalação/normas , Anestesiologia/instrumentação , Anestesiologia/métodos , Anestésicos Inalatórios/administração & dosagem , Anestésicos Inalatórios/efeitos adversos , Calibragem , Lista de Checagem , Alarmes Clínicos , Documentação , Falha de Equipamento , Segurança de Equipamentos , Controle de Formulários e Registros , Depuradores de Gases/normas , Humanos , Monitorização Intraoperatória/instrumentação , Monitorização Intraoperatória/normas , Nebulizadores e Vaporizadores/normas , Oxigenoterapia/instrumentação , Segurança do Paciente/normas , Medicação Pré-Anestésica/normas , Cuidados Pré-Operatórios/métodos , Espanha , Ventiladores Mecânicos/normasRESUMO
BACKGROUND: The objective of this study was to compare the distribution of aerosol delivered via a powered nasal nebulizer device in 5 fresh frozen-cadaver heads (10 total sides). METHODS: Nasoneb® (Medinvent, St. Paul, MN) was used to deliver a total volume of 10 mL (9 mL saline and 1 mL of 10% fluorescein). Aerosol distribution was assessed in 3 trials: (1) unoperated nose; (2) post-functional endoscopic sinus surgery (FESS); and (3) post-FESS with endoscopic modified Lothrop procedure (EML). Two independent observers rated the distribution of the fluorescein-dyed saline in the anterior nasal cavity (ANC), olfactory cleft (OC), middle meatus (MM), sphenoethmoid recess (SER), nasopharynx (NP), along with maxillary sinus (MS), ethmoid cavity (EC), sphenoid sinus (SS), frontal sinus (FS), and frontal neo-ostium (F-NEO) in the operated specimens. RESULTS: The nebulizer consistently delivered aerosolized saline to the ANC, MM/EC, and SER/SS across the 3 trials. A statistically significant increase in delivery was noted to the MM (p = 0.044) post-FESS. In addition, a statistically significant increase in delivery to the F-NEO was noted post-FESS with EML (p = 0.001). Multiplicity adjustment done for the FESS group showed statistically superior delivery to the EC vs OC (p = 0.031) and FS (p = 0.02) and to the SS vs FS (p = 0.031). Multiplicity adjustment after FESS with EML improved delivery to the FS, resulting in no statistical difference in aerosol delivery between F-NEO and EC or SS. CONCLUSION: The nebulizer consistently delivered aerosolized saline to multiple nasal subsites, with improvement in delivery seen to the middle meatal region after FESS and F-NEO after FESS with EML. This may have important implications for the delivery of topical medications to the paranasal sinuses in the postoperative setting.
Assuntos
Administração Intranasal/instrumentação , Aerossóis/farmacocinética , Fluoresceína/farmacocinética , Corantes Fluorescentes/farmacocinética , Nebulizadores e Vaporizadores/normas , Cloreto de Sódio/farmacocinética , Aerossóis/administração & dosagem , Cadáver , Estudos de Casos e Controles , Fluoresceína/administração & dosagem , Corantes Fluorescentes/administração & dosagem , Humanos , Nariz/cirurgia , Estudos Prospectivos , Cloreto de Sódio/administração & dosagemRESUMO
The correct handling of dry powder inhalers (DPIs) is crucial for efficient therapy, and acceptance of the device can improve compliance. The handling of seven different dry powder inhalers was studied in 72 patients with asthma and chronic obstructive pulmonary disease (COPD). The aim of this study was to identify possible handling errors and investigate patient preferences. Patients inhaled twice with each inhaler; first after reading the device leaflet, and second after device handling was explained by the investigator. The investigator identified handling errors and critical handling errors, which might lead to insufficient or no dose delivery. Afterward, the patients selected their preferred device and judged different aspects of device handling. The lowest number of patients with critical handling errors was observed for the Diskus/Accuhaler, the highest numbers for the Jethaler and the Easyhaler (% of patients during first/second use): Diskus/Accuhaler 25%/13.9% (group A) and 38.9%/8.3% (group B); Clickhaler 50.0%/52.8%, Cyclohaler 58.3%/13.9%, Jethaler 66.7%/30.6% (group A) and Benosid N Inhaler 52.8%/22.2%, Novolizer 52.8%/25.0%, Easyhaler 72.2%/47.2% (group B). Device handling improved after instruction by the investigator. Device handling and preferences of patients closely correlated in this study. Both devices producing the lowest numbers of handling errors (Diskus/Accuhaler and Clickhaler) had the highest preference by the subjects (score from 1 = very good to 7 = very bad): Diskus/Accuhaler 2.21 (group A) and 2.02 (group B); Clickhaler 2.21, Cyclohaler 2.80, Jethaler 3.16 (group A); Novolizer 2.33, Easyhaler 2.37, Benosid N Inhaler 2.43 (group B). Critical handling errors may reduce therapy outcome due to a reduced dose delivery. In addition, reduced patients acceptance of a device, being dependent on device handling, may have a similar effect by reducing patients' compliance.